glp 1 gip gcg receptor agonist GLP-1 Orals and Multi-Agonists: Advancing Next-Gen Weight Loss Therapies with Humanized Models Polyagonists Enable Increasingly Effective Treatment

Berthelsen, K.K

Additionally, newer weight loss drugs appear safe to use before bariatric surgery

While higher-income individuals may manage to afford GLP-1s OOP, lower-income individuals who are more likely to be affected by obesity will face significant access barriers

[DOI] [PubMed] [Google Scholar] [220].Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58 (2009) 22582266

doi: 10.1111/dom.13034 [DOI] [PubMed] [Google Scholar] 23.Frias JP, Bastyr EJ 3rd, Vignati L, et al